Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Topotecan 3Radiotherapy 3Pemetrexed 3osimertinib 2WP 744 2Radiation 2Busulfan 2AZD3759 2tipifarnib 1sintilimab 1pembrolizumab 1peginterferon alfa-2b 1omburtamab I-131 1mafosfamide 1immunotoxin LMB-7 1gallium citrate 1azeliragon 1avelumab 1adavosertib 1Vitamin B 12 1Vinorelbine 1Trastuzumab 1Temozolomide 1Specimen Handling 1Rituximab 1Pentetic Acid 1Melphalan 1Magnetic Resonance Spectroscopy 1Interferons 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Meningeal Carcinomatosis × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡